COMMUNIQUÉS West-GlobeNewswire

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
09/05/2026
Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care [...]
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
09/05/2026
ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro [...]
iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
09/05/2026
May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research [...]
Open Peer-Review Exposes UPV Ethics Committee’s Dilemma: Suppress a 33 Year Recognized Breakthrough or Acknowledge Reviewer’s Ethical Violations and Remit Final Judgement to the Known Dataset Test to Save Millions of Lives and Billions of Euros
09/05/2026
Crosetto Foundation calls for public transparency after TBPET reviewers rejected a Known Dataset Test abstract while failing to refute its calculations, technical evidence, or documented comparisons. DALLAS, May 08, [...]
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 10, 2026
08/05/2026
REGULATED INFORMATION May 8, 2026, 10:05pm CET / 4:05pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual [...]
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
08/05/2026
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and [...]
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
08/05/2026
White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra- [...]
Premier Health Announces Termination of Forbearance Agreements With Principal Lenders and the Continuance of Its Strategic Review Process
08/05/2026
MONTRÉAL, May 08, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health”), a leading Canadian health tech company, announced that as previously disclosed in its most [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/05/2026
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced [...]
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08/05/2026
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
08/05/2026
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- ATLANTA, May 08, 2026 (GLOBE [...]
James Cacioppo Files Updated Early Warning Report
08/05/2026
BOCA RATON, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- James Cacioppo, Chief Executive Officer, Chairman, and Founder of Jushi Holdings Inc. (the " Company "), announced today that he has filed an early warning report on [...]
TOMI Environmental Solutions, Inc. Reports First Quarter 2026 Financial Results and Announces Transformative Letter of Intent to Merge with Carbonium Core, Inc.
08/05/2026
FREDERICK, Md., May 08, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT [...]
FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
08/05/2026
Recommendations aim to help provide clearer safety information for use during pregnancy White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a final guidance for industry, [...]
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
08/05/2026
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative [...]
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/05/2026
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights [...]
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
08/05/2026
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/05/2026
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering
08/05/2026
First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletion All non-human primates (6 of 6) exhibited [...]

Pages